2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2206

Joint Repair While Initiating Biologic Therapy in Rheumatoid Arthritis
Abstract Number: 2207

Detecting Hand Joint Ankylosis in Radiographic Images Using Deep Learning: A Step in Development of Automatic Radiographic Scoring System for Bone Destruction
Abstract Number: 2208

Novel Fluorescence Optical Imaging Scoring System of Inflammation in the Hand and Wrist Is in Patients with Rheumatoid Arthritis – Agreement with Ultrasonography and Sensitivity to Change
Abstract Number: 2209

Fluorescence Optical Imaging Xiralite® Is Helpful in the Decision for Rituximab Re-Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 2210

Effects of Anti-Citrullinated Peptide Antibody (ACPA) on Bone Microstructure in Rheumatoid Arthritis: A HR-pQCT Study
Abstract Number: 2211

Technetium Tc 99m Tilmanocept: A Targeted Immunodiagnostic Radiopharmaceutical for the Assessment of Synovial Macrophage Activity in Rheumatoid Arthritis
Abstract Number: 2212

Feasibility and Performance of HR-pQCT-Derived Joint Space Width Measurement As Outcome Parameter in Arthropathic Disease – Lessons from Hemochromatosis Arthropathy
Abstract Number: 2213

Usefulness of Shoulder Radiographs to Aid in Determining Need for Advanced Imaging to Detect Operable or Inoperable Full-Thickness Rotator Cuff Tears
Abstract Number: 2214

Lung Involvement in Primary Sjögren’s Syndrome: Spectrum of Pulmonary Abnormalities and Computed Tomography Findings
Abstract Number: 2215

Evaluation of Left Ventricular Systolic and Diastolic Myocardial Function in Patients with Ankylosing Spondylitis By Speckle-Tracking Echocardiography
Abstract Number: 2216

Detection of Left Ventricular Regional Function in Primary Sjögren’s Syndrome Patients without Cardiac Symptons, As Assessed By Feature Tracking Cardiac Magnetic Resonance Imaging
Abstract Number: 2217

Clinical Characteristics of Early Onset Gout in Outpatient Setting
Abstract Number: 2218

Use of Anakinra in Hospitalized Patients with Acute Crystalline Arthritis
Abstract Number: 2219

Safety, Pharmacokinetics and Pharmacodynamics of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor, in Healthy Volunteers
Abstract Number: 2220

Gout, Flares and Allopurinol Use: A Population Based Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].